Policy Engagement »

SWHR Recommends ICER Delay Report on Endometriosis Treatments

May 31, 2018

In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence report assessing new endometriosis therapies until they have been more thoroughly studied by Food and Drug Administration (FDA). Examining the draft report in detail, SWHR noted areas where ICER’s methodology, modeling techniques, and key inputs could be refined.

SWHR pointed out the limitations within the draft evidence report that make a clear assessment of the new therapies difficult. For example, ICER’s analysis compared the cost-effectiveness of elagolix to no treatment (i.e., placebo) and was unable to compare to other treatments due to lack of data. Delaying the report until more comprehensive studies are completed would allow ICER to produce a more thorough assessment comparing the cost-effectiveness of treatments. SWHR also made recommendations to ICER for improving or refining future analyses.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

Download

In comments to the Institute for Clinical and Economic Review (ICER), SWHR recommended the organization delay finalizing its draft evidence report assessing new endometriosis therapies until they have been more thoroughly studied by Food and Drug Administration (FDA). Examining the draft report in detail, SWHR noted areas where ICER’s methodology, modeling techniques, and key inputs could be refined.

SWHR pointed out the limitations within the draft evidence report that make a clear assessment of the new therapies difficult. For example, ICER’s analysis compared the cost-effectiveness of elagolix to no treatment (i.e., placebo) and was unable to compare to other treatments due to lack of data. Delaying the report until more comprehensive studies are completed would allow ICER to produce a more thorough assessment comparing the cost-effectiveness of treatments. SWHR also made recommendations to ICER for improving or refining future analyses.

Learn more about endometriosis through the work of SWHR’s Interdisciplinary Network on Endometriosis and Fibroids.

SWHR’s ICER Engagement

Policy Engagement
SWHR Provides Feedback to ICER on Draft Evidence Report on Treatments for Alzheimer’s Disease
02.07.23
SWHR provided feedback to the Institute for Clinical and Economic Review (ICER) in response to its Draft Evidence Report assessing the comparative clinical effectiveness and value of emerging anti-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. READ THE Letter
Blog Post
SWHR Releases Updated Health Care Value Assessment Principles
10.27.22
These new Policy Principles build upon SWHR's 2019 principles, now accounting for changes in the health care value assessment landscape that specifically impact women.
Policy Engagement
SWHR’s 2022 Health Care Value Assessment Principles
10.27.22
These 2022 Principles reflect on the current health care value assessment landscape and identify additional opportunities to promote patient-centered value, and incorporate factors that are relevant for women.
Blog Post
Women’s Health Policy Agenda Expands Focus Areas for 2022
03.28.22
The 2022 Women’s Health Policy Agenda outlines policy priorities across five key areas—public health, research and clinical trials, lifespan issues, coverage and access, and the biomedical research workforce.
Blog Post
Integrating Women into Health Care Research, Quality Improvement, and Value Assessment
06.30.21
Across research and health policy, the unique needs of women as patients, caregivers, and primary health care decision-makers for their families are receiving more attention.
Blog Post
Women and Value Assessment: Striving to Capture the Patient Experience
06.30.20
SWHR hosted three value assessment experts at its recent policy meeting to discuss the integration of women’s health priorities into assessments of new health care innovations.
Blog Post
ICER’s Value Framework: A Work in Progress for Women’s Health
05.29.20
ICER's updated value assessment framework embraces several of SWHR’s recommendations, but more work remains to adequately evaluate the value of health care interventions for women.
Blog Post
No ‘Best’ Framework for Assessing Value of Health Care Innovations, NPC Report Says
01.08.20
A report from the National Pharmaceutical Council (NPC) concludes that there is no “best” framework for determining the value of a health care product.
Blog Post
SWHR Develops Principles to Ensure Health Care Value Assessments Work for Women
11.04.19
When a new health care innovation comes to market, how do patients, health care providers, and health care payers determine its value?